Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Single Cell Multiomics Market: Immuno-Oncology Research Growth, Droplet-Based Platform Adoption, and Population-Scale Multiomic Research Infrastructure Investment to Drive Exceptional Market Expansion Through 2035

The global Single Cell Multiomics Market was valued at USD 3.2 billion in 2025 and is projected to expand at an exceptional CAGR of 20.5% to reach approximately USD 17.1 billion by 2035, driven by sustained immuno-oncology and cell biology research growth, growing droplet-based microfluidics platform adoption, and continued national research infrastructure investment in population-scale multiomic data generation. The market encompasses single-cell genomics, proteomics, metabolomics, and transcriptomics products deployed across oncology, immunology, neurology, and cell biology applications. Demand for the category continues to be shaped by a diverse mix of academic, pharmaceutical, and clinical research accounts operating across multiple disease areas and research applications.

The Single Cell Multiomics Market’s exceptional 20.5% CAGR — the fastest of any omics category in this report series — reflects the technology’s unique ability to simultaneously capture multiple molecular layers from the same individual cell, sustaining structured integrated-platform demand above single-modality single-cell technique baseline. The U.S. National Institutes of Health reported in 2026 that its All of Us Research Program had entered what the agency described as the multiomics era, combining whole genome sequencing from more than 535,000 participants with newly added proteomics data from nearly 10,000 participants and RNA sequencing data from nearly 9,000 participants — a national-scale demonstration of the combined-modality data generation that single-cell multiomics platforms are increasingly expected to support at the individual-cell level.

Executive Snapshot

How does immuno-oncology research demand drive single cell multiomics market growth?
Single-cell multiomics platforms allow researchers to simultaneously characterize the genomic, transcriptomic, and proteomic state of individual immune and tumor cells, sustaining the largest single application driver for single-cell multiomics platforms, with continued immunotherapy development and precision oncology research investment sustaining above-baseline immuno-oncology-application procurement. This trend has become increasingly pronounced over the past several reporting periods as research funding priorities and technology capability continue to evolve together.

What role does droplet-based microfluidics platform adoption play in market growth?
Droplet-based microfluidics technology sustains structured demand from researchers requiring high-throughput, cost-efficient single-cell multiomic capture, with continued instrument throughput and cost-efficiency improvements sustaining above-baseline droplet-based-platform single-cell multiomics procurement above nanowell and combinatorial indexing technique baseline. Researchers and platform developers expect this pattern to persist through the remainder of the forecast period as underlying scientific and funding priorities remain in place.

How does population-scale multiomic research infrastructure investment sustain market growth?
National genomics research programmes generating combined genomic, transcriptomic, and proteomic data from large participant cohorts sustain structured single-cell multiomics platform demand, with continued national research infrastructure investment — including NIH’s All of Us Research Program multiomics expansion — sustaining above-baseline population-scale single-cell multiomics procurement. This factor is widely viewed within the research community as one of the more durable structural drivers shaping platform adoption across academic and commercial accounts.

What is driving demand for single cell multiomics in neurology research?
Neurology research applications characterizing neuronal cell diversity across multiple molecular layers simultaneously sustain structured single-cell multiomics demand from academic and pharmaceutical neuroscience research accounts, with continued neurodegenerative disease research investment sustaining above-baseline neurology-application procurement. This dynamic has been reinforced by broader shifts in how research institutions and funding agencies prioritize investment in next-generation molecular profiling capability.

How does spatial-omics platform integration sustain the single cell multiomics market?
Platforms that combine single-cell multiomic profiling with spatial context sustain structured demand from researchers seeking both cellular-resolution molecular data and tissue-location information, with continued spatial-omics platform integration innovation sustaining above-baseline integrated single-cell multiomics market value growth. Analysts covering the life sciences tools sector expect this trend to remain a persistent feature of demand patterns through 2035.

Which single cell multiomics market segments are growing fastest?
Droplet-based microfluidics platforms from throughput and cost-efficiency demand; oncology and immunology application segments from sustained disease research investment; spatial-omics platform integration from combined cellular-and-tissue-context demand; and pharmaceutical and biotechnology end-user accounts from drug discovery application demand are the fastest-growing segments. This factor is expected to remain relevant even as the broader research funding environment fluctuates over the coming decade.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Single Cell Multiomics Market

  • Oncology and immunology applications sustaining the largest-value single-cell multiomics demand: Immuno-oncology and precision oncology research funding sustaining dominant oncology-and-immunology-sector single-cell multiomics procurement value above other application categories. This pattern is consistent with broader trends observed across adjacent life sciences research technology categories.
  • Droplet-based microfluidics platforms sustaining structured throughput-efficiency demand growth: High-throughput, cost-efficient single-cell multiomic capture technology sustaining structured platform adoption above nanowell and combinatorial indexing technique baseline. Platform developers with technical depth and established research relationships are generally best positioned to capture this structural advantage.
  • Population-scale research infrastructure sustaining structured national-programme single-cell multiomics demand growth: National genomics research programme data collection, including NIH’s multiomics-era All of Us Research Program expansion, sustaining structured single-cell multiomics platform demand. This dynamic is expected to persist as research applications continue to mature and expand into translational settings.
  • Neurology research applications sustaining structured above-baseline single-cell multiomics demand growth: Neuronal cell diversity research across multiple molecular layers sustaining structured single-cell multiomics demand from neuroscience research accounts. Industry participants view this as one of the more stable structural features of the category’s demand base.
  • Spatial-omics platform integration sustaining above-cellular-only-profiling market value growth: Combined cellular-resolution and tissue-location profiling technology sustaining structured single-cell multiomics market value growth above cellular-only profiling baseline. This trend has held steady across recent reporting periods and shows limited signs of reversal.
  • Pharmaceutical and biotechnology drug discovery applications sustaining structured commercial demand growth: Target validation and drug discovery applications sustaining structured single-cell multiomics demand from pharmaceutical and biotechnology research accounts. Platform developers able to adapt to this dynamic are generally sustaining stronger customer retention outcomes.

Market Segmentation: Single Cell Multiomics Market

By Product
  • Single-Cell Genomics
  • Single-Cell Proteomics
  • Single-Cell Metabolomics
  • Single-Cell Transcriptomics
By Technology
  • Droplet-Based Microfluidics
  • Nanowell / Combinatorial Indexing
  • Spatial-Omics Platforms
  • Others
By Application
  • Immunology
  • Cell Biology
  • Oncology
  • Neurology
  • Others
By End User
  • Hospital and Diagnostic Laboratories
  • Academic and Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Others
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Single Cell Multiomics Market

  1. Sustained immuno-oncology research funding driving combined genomic-transcriptomic-proteomic cell profiling demand: Immunotherapy development and precision oncology research sustaining structured single-cell multiomics demand above discretionary research technology demand growth. This driver is expected to remain structurally significant through the full forecast horizon.
  2. Growing droplet-based microfluidics platform throughput and cost-efficiency improvements: High-throughput, cost-efficient instrumentation sustaining structured single-cell multiomics platform adoption above lower-throughput technique baseline. Platform developers investing ahead of this trend are generally capturing disproportionate customer retention benefits.
  3. Continued national research infrastructure investment incorporating population-scale multiomic data generation: Public research programme incorporation of combined-modality single-cell data, including NIH’s All of Us Research Program expansion, sustaining structured academic single-cell multiomics procurement. This factor complements several of the other structural drivers shaping the category’s growth trajectory.
  4. Sustained neurodegenerative disease research investment supporting structured neurology application demand growth: Neuronal cell diversity research across multiple molecular layers sustaining structured single-cell multiomics demand from neuroscience research accounts. Industry participants broadly expect this driver to sustain its relevance through 2035.
  5. Growing spatial-omics platform integration innovation sustaining structured combined-context demand growth: Cellular-resolution and tissue-location combined profiling technology sustaining structured single-cell multiomics market value growth. This trend is reinforced by parallel developments across adjacent research technology and funding categories.
  6. Continued pharmaceutical drug discovery pipeline investment sustaining structured commercial platform demand: Target validation and drug discovery applications sustaining structured single-cell multiomics demand from pharmaceutical and biotechnology research accounts. Continued investment against this driver is expected from both established and emerging platform developers alike.

Regional Outlook: Single Cell Multiomics Market

  • North America: United States anchors North American single-cell multiomics demand from academic immuno-oncology research centers and NIH-funded population health programmes incorporating combined-modality single-cell data, sustaining structured regional platform procurement. Regional research institutions continue to invest in platform capacity and technical staff to support growing demand from this application base.
  • Europe: Germany, the United Kingdom, and France anchor European single-cell multiomics demand from academic research institutions and biopharmaceutical research and development centers, sustaining structured regional platform procurement. This regional demand profile is expected to remain broadly stable through the forecast period as research funding priorities continue to favor the category.
  • Asia-Pacific: China, Japan, and South Korea anchor Asia-Pacific single-cell multiomics demand and supply from growing precision oncology research capacity and biotechnology industry investment, sustaining the largest regional single-cell multiomics consumption base. Regional research institutions continue to invest in platform capacity and technical staff to support growing demand from this application base.
  • Latin America: Brazil anchors Latin American single-cell multiomics demand from academic translational research institution accounts, sustaining structured regional platform procurement. This regional demand profile is expected to remain broadly stable through the forecast period as research funding priorities continue to favor the category.

Competitive Landscape: Single Cell Multiomics Market

Key Players: 10x Genomics, Inc., Mission Bio, Inc., Parse Biosciences, Standard BioTools Inc., BD (Becton, Dickinson and Company), Illumina, Inc., Bio-Rad Laboratories, Inc., Scale Biosciences, Inc., Vizgen, Inc., Akoya Biosciences, Inc., Fluent BioSciences, Inc., Singleron Biotechnologies

  • Mission Bio, Inc. [March 2026] — confirmed continued expansion of its single-cell multiomics platform combining genomic and proteomic profiling, with the company noting that immuno-oncology customer demand is sustaining above-historical order growth from academic and pharmaceutical research accounts.
  • 10x Genomics, Inc. [December 2025] — reported continued investment in droplet-based multiomics capture technology, with the company noting sustained customer demand from researchers seeking combined genomic, transcriptomic, and proteomic single-cell profiling.
  • Parse Biosciences [September 2025] — confirmed continued expansion of its combinatorial-indexing single-cell multiomics platform for high-throughput research applications, with the company reporting structured customer order growth.

Consultant POV

The Single Cell Multiomics Market’s exceptional 20.5% CAGR from USD 3.2 billion in 2025 toward approximately USD 17.1 billion by 2035 — the fastest growth rate across the omics markets covered in this series — is anchored in sustained immuno-oncology research growth, growing droplet-based platform adoption, and continued population-scale multiomic research infrastructure investment such as NIH’s All of Us Research Program. Continued product investment from platform developers such as Mission Bio, Inc., 10x Genomics, Inc., and Parse Biosciences confirm the Single Cell Multiomics Market will sustain exceptional growth through 2035. Buyers and investors tracking the category are advised to monitor national research infrastructure funding, platform capability announcements, and translational research adoption for further confirmation of this trajectory.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report